ResultsIQ › Latest results › Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited Q2 FY27 results deck summary
NSE: AKUMS · BSE: 544222
Results deck of 2 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue rose 31.9% YoY to ₹1,342 cr and PAT 168.3% to ₹115 cr, led by CDMO volume growth.
Key takeaways
- No numeric guidance Management gave no numeric revenue or margin guidance, only that it remains optimistic of delivering positive results.
- Sequential growth Revenue rose 15.1% QoQ to ₹1,342 cr from ₹1,167 cr and EBITDA rose 11.5% QoQ to ₹195 cr from ₹175 cr.
Akums Drugs and Pharmaceuticals Limited Q2 FY27 results
As filed: Revenue ₹1,342 cr (+32% year on year), EBITDA ₹195 cr (+105% year on year), PAT ₹115 cr (+166% year on year), EBITDA margin 14.5% (+517 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹1,167 cr (+14% year on year), EBITDA ₹175 cr (+35% year on year), PAT ₹101 cr (+55% year on year), EBITDA margin 15.0% (+238 bps). Score 69 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 238 bps year on year. Consolidated profit +55% but standalone 0%. Share price after the results: +8.2% in 30 days (Nifty 500: −2.3%).
- Q4 FY26: Revenue ₹1,158 cr (+10% year on year), EBITDA ₹152 cr (+61% year on year), PAT ₹81.3 cr (−46% year on year), EBITDA margin 13.1% (+420 bps). Score 49 of 100, In line with trend. EBITDA margin rose 420 bps year on year. Other income 29% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: +15.3% in 29 days (Nifty 500: +1.0%).
- Q3 FY26: Revenue ₹1,160 cr (+15% year on year), EBITDA ₹147 cr (+21% year on year), PAT ₹67.7 cr (+37% year on year), EBITDA margin 12.7% (+68 bps). Score 53 of 100, In line with trend. EBITDA margin rose 68 bps year on year. Other income 34% of PBT. Consolidated profit +3% but standalone -31%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +4.2% in 28 days (Nifty 500: −8.2%).
- Q2 FY26: Revenue ₹1,018 cr (−1% year on year), EBITDA ₹95.0 cr (−22% year on year), PAT ₹43.0 cr (−36% year on year), EBITDA margin 9.3% (−248 bps). Score 7 of 100, Below trend. EBITDA margin fell 248 bps year on year. Other income 48% of PBT. Not enough history for a trend yet: scored on growth alone. Profit fell 34% from last quarter. Share price after the results: −3.3% in 29 days (Nifty 500: −0.4%).
- Q1 FY26: Revenue ₹1,024 cr (0% year on year), EBITDA ₹129 cr (+2% year on year), PAT ₹65.0 cr (+7% year on year), EBITDA margin 12.6% (+13 bps). Score 28 of 100, Below trend. EBITDA margin rose 13 bps year on year. Other income 28% of PBT. Not enough history for a trend yet: scored on growth alone. Revenue fell 3% from last quarter. Share price after the results: −4.2% in 28 days (Nifty 500: +1.7%).
- Q4 FY25: Revenue ₹1,056 cr, EBITDA ₹94.0 cr, PAT ₹150 cr, EBITDA margin 8.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,056 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −1.1% in 30 days (Nifty 500: +1.7%).
- Q3 FY25: Revenue ₹1,010 cr, EBITDA ₹121 cr, PAT ₹66.0 cr, EBITDA margin 12.0%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,010 cr). Scored once a year-earlier consolidated quarter exists.
Past price moves after results do not indicate future moves. Not a recommendation.
Akums Drugs and Pharmaceuticals Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (3 Nov 2026), Results deck (2 Nov 2026)
- Q1 FY27: Earnings call (10 Aug 2026), Results deck (8 Aug 2026)
- Q4 FY26: Earnings call (18 May 2026), Results deck (14 May 2026)
- Q3 FY26: Earnings call (16 Feb 2026), Results deck (13 Feb 2026)
- Q2 FY26: Earnings call (14 Nov 2025), Results deck (13 Nov 2025)
- Q1 FY26: Earnings call (11 Aug 2025), Results deck (8 Aug 2025)
- Q4 FY25: Earnings call (27 May 2025), Results deck (26 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.